American Society of Hirudotherapy

Leech C-Type Lectin

C-type lectin domain protein identified in Hirudo medicinalis salivary transcriptome — putative carbohydrate / glycoprotein binder.

Preclinical / mechanisticLast updated: 2026-05-26 · Reviewed by ASH Editorial Board
Molecular weight of Leech C-Type Lectin compared with other characterized leech-derived compoundsHementerin80 kDaHementin80 kDaHementin-Like Protein (HLP-1)80 kDaLeech Collagenase70 kDaHaemadipsa yanyuanensis Progr…70 kDaLeech Apyrase67 kDaCalin65 kDaHyaluronidase60 kDaAntithrombin III binding prot…58 kDaCollagenolytic Fibrinolysin55 kDaLeech Thrombospondin-Like Pro…50 kDaLeech C-Type Lectin20 kDa
Molecular weight (kilodaltons) of Leech C-Type Lectin (highlighted) alongside other characterized leech salivary compounds. Smaller proteins/peptides generally diffuse and act faster.

Mechanistic Evidence Box

Preclinical / mechanistic
Page type
Compound profile
Evidence type
C-type lectin domain protein identified in Hirudo medicinalis salivary transcriptome — putative carbohydrate / glycoprotein binder.
Evidence level
Mechanistic discussion
Drug vs leech
Purified natural compound

Clinical translation limit

This C-type lectin is identified at the sequence level only. Hypothesized glycan-binding roles are NOT clinically validated. No FDA-approved derivative exists.

Molecular Profile

Category
Other
Evidence tier
Preclinical
Molecular weight
20,000 Da
Source species
Hirudo medicinalis
Discovered
2018
Leech C-Type Lectin molecular structure

Biological Targets

  • sialylated and galactose-containing glycoconjugates (predicted)

External Resources

    Related Other Compounds

    This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.